



Investor Presentation

Annual General Meeting
27th November 2024

**Treatment focused.
Technology driven.**



Disclaimer



This document has been prepared as a summary only and does not contain all information about the Company's assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company's securities. This document should be read in conjunction with any public announcements and reports (including financial reports and disclosure documents) released by SomnoMed Limited. The securities issued by the Company are considered speculative and there is no guarantee that they will make a return on the capital invested, that dividends will be paid on the Shares or that there will be an increase in the value of the Shares in the future.

Some of the statements contained in this release are forward-looking statements. Forward looking statements include but are not limited to, statements concerning estimates of future sales, expected revenues and costs, statements relating to the continued advancement of the Company's operations and other statements which are not historical facts. When used in this document, and on other published information of the Company, the words such as "aim", "could", "estimate", "expect", "intend", "target", "forecast", "future", "will", "may", "potential", "should" and similar expressions are forward-looking statements.

Although the company believes that its expectations reflected in the forward-looking statements are reasonable, such statements involve risk and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Various factors could cause actual results and projections of future performance to differ from these forward-looking statements as a result of known and unknown risks, uncertainties and other factors not anticipated by the Company or disclosed in the Company's published material. Many of these factors are beyond the control of SomnoMed Limited and may involve subjective judgement and assumptions as to future events, which may or may not be correct.


The Company does not purport to give financial or investment advice. No account has been taken of the objectives, financial situation or needs of any recipient of this document.

Recipients of this document should carefully consider whether the securities issued by the Company are an appropriate investment for them in light of their personal circumstances, including their financial and taxation position.

Trading and Company Update




Building the foundations for profitable growth



¹ EBITDA excludes AASB16 leases, share/option expenses, unrealised foreign exchange gain/loss, one off restructuring costs and discontinued operations and consistent with aspirations stated in Investor Presentation 9/4/24

Core Business strengthens in Q1 FY25



Revenue growth

Revenue growth of +18.2% YoY (+20.3% CC)

Earnings growth

Additional revenue and disciplined cost management generating Q1 FY25 EBITDA² > FY23 and FY24 respective EBITDA²

Capacity uplift

>30% increase in manufacturing capacity

Positive operating cashflow

Improved operating cash position compared to FY23 and FY24; Q1 FCF positive

New top tier leadership team



Jonathan Vowels: VP Manufacturing and Operations

- Former Operations Director SEA British American Tobacco
- Over 25 years manufacturing and supply chain experience



Ye-Fei Guo: Chief Financial Officer

- Former VP Finance at Brookfield, trained at PwC
- CA, over 20 years in finance, over 10 years at Brookfield, ASX and company secretarial experience



Janice Hiskett-Jones: Chief People Officer

- Former Interim CPO at SunRice
- Over 25 years HR experience specialising in incentives



Keshan Gunasinghe: Chief Product Officer

- Former VP R&D Kenvue and J&J Consumer Health Asia
- Over 20 years R&D experience J&J Asia




Mary Kennell: Global Director, Quality Assurance and Regulatory Affairs

- Former Head of Regulatory Affairs and Quality at Alcon
- Over 18 years regulatory and quality experience at medical device and pharma companies



FY25 Revised Guidance



FY25 original guidance

Revenue

c. \$100m

EBITDA¹

>\$5m

Capex

\$3-4m

FY25 guidance upgrade

Revenue

c. \$105m

vs. \$91.7m FY24

EBITDA¹

>\$7m

vs. \$0.6m FY24

Capex

\$3-4m

Rest Assure[®]



Rest Assure® status Oct-24:

- FDA cleared Rest Assure® as the first oral device with built-in compliance monitoring
- Clearance includes the oral device and software platform incl. patient app, physician platform, docking station and cloud systems

Rest Assure® next steps:

- New FDA 510k submission underway for efficacy monitoring, centred on a US clinical trial
- Costs for trial included in budget



For further information please contact:

Investor Relations: IR@somnomed.com.au